326 related articles for article (PubMed ID: 28550758)
21. The phenotypic heterogeneity of severe hemophilia.
Jayandharan GR; Srivastava A
Semin Thromb Hemost; 2008 Feb; 34(1):128-41. PubMed ID: 18393149
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of platelet activation in hemophilia A.
van Bladel ER; Roest M; de Groot PG; Schutgens RE
Haematologica; 2011 Jun; 96(6):888-95. PubMed ID: 21422116
[TBL] [Abstract][Full Text] [Related]
23. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
[TBL] [Abstract][Full Text] [Related]
24. Increased bone resorption in hemophilia.
Rodriguez-Merchan EC; Valentino LA
Blood Rev; 2019 Jan; 33():6-10. PubMed ID: 29857920
[TBL] [Abstract][Full Text] [Related]
25. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
26. The prolonged bleeding time in hemophilia A: comparison of two measuring technics and clinical associations.
Smith PS; Baglini R; Meissner GF
Am J Clin Pathol; 1985 Feb; 83(2):211-5. PubMed ID: 3918435
[TBL] [Abstract][Full Text] [Related]
27. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Lyde RB; Ahn HS; Vo KK; Jarocha DJ; Tkaczynski J; Treffeisen E; Sullivan SK; Camire RM; Sabatino DE; French DL; Poncz M
Blood Adv; 2019 May; 3(9):1368-1378. PubMed ID: 31036722
[TBL] [Abstract][Full Text] [Related]
28. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
29. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency.
Croteau SE; Frelinger AL; Gerrits AJ; Michelson AD
J Thromb Haemost; 2021 Apr; 19(4):976-982. PubMed ID: 33370471
[TBL] [Abstract][Full Text] [Related]
30. Thrombocytopathy leading to impaired in vivo haemostasis and thrombosis in platelet type von Willebrand disease.
Kaur H; Corscadden K; Ware J; Othman M
Thromb Haemost; 2017 Feb; 117(3):543-555. PubMed ID: 28004055
[TBL] [Abstract][Full Text] [Related]
31. Hemophilia A and B are associated with abnormal spatial dynamics of clot growth.
Ovanesov MV; Krasotkina JV; Ul'yanova LI; Abushinova KV; Plyushch OP; Domogatskii SP; Vorob'ev AI; Ataullakhanov FI
Biochim Biophys Acta; 2002 Aug; 1572(1):45-57. PubMed ID: 12204332
[TBL] [Abstract][Full Text] [Related]
32. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.
Lewis SJ; Stephens E; Florou G; Macartney NJ; Hathaway LS; Knipping J; Collins PW
Br J Haematol; 2007 Sep; 138(6):775-82. PubMed ID: 17672884
[TBL] [Abstract][Full Text] [Related]
33. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Aymonnier K; Kawecki C; Venisse L; Boulaftali Y; Christophe OD; Lenting PJ; Arocas V; de Raucourt E; Denis CV; Bouton MC
Blood; 2019 Nov; 134(19):1632-1644. PubMed ID: 31383642
[TBL] [Abstract][Full Text] [Related]
34. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Allen GA; Persson E; Campbell RA; Ezban M; Hedner U; Wolberg AS
Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):683-9. PubMed ID: 17204663
[TBL] [Abstract][Full Text] [Related]
35. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
[TBL] [Abstract][Full Text] [Related]
36. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
Sehgal A; Barros S; Ivanciu L; Cooley B; Qin J; Racie T; Hettinger J; Carioto M; Jiang Y; Brodsky J; Prabhala H; Zhang X; Attarwala H; Hutabarat R; Foster D; Milstein S; Charisse K; Kuchimanchi S; Maier MA; Nechev L; Kandasamy P; Kel'in AV; Nair JK; Rajeev KG; Manoharan M; Meyers R; Sorensen B; Simon AR; Dargaud Y; Negrier C; Camire RM; Akinc A
Nat Med; 2015 May; 21(5):492-7. PubMed ID: 25849132
[TBL] [Abstract][Full Text] [Related]
37. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
38. Association of the hemophilia A carrier state and hemorrhagic thrombocytopathy with dilatation of the platelet membrane complex.
Melamed I; Djaldetti M; Joshua H; Seligsohn U
Acta Haematol; 1984; 71(6):381-7. PubMed ID: 6433619
[TBL] [Abstract][Full Text] [Related]
39. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics.
Tarandovskiy ID; Balandina AN; Kopylov KG; Konyashina NI; Kumskova MA; Panteleev MA; Ataullakhanov FI
Thromb Res; 2013 Jun; 131(6):e274-80. PubMed ID: 23611257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
